Previous

BioTheryX doses first patient in Ph1 study investigating lead protein degrader candidate BTX-1188
Next

Turning Point Therapeutics announces FDA clearance of IND application for combination of Elzovantinib and Aumolertinib in EGFR mutant MET-amplified non-small cell lung cancer